Depo medrol
PreclinicalSmall molecule
Depo medrol is one of 41 small molecule programs targeting Tendinitis. It is currently in Preclinical.
2
Indications
7
Total Trials
1
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
36 competitors in Back Pain
#DrugCompanyPhaseTrials
1Aleve
Jazz PharmaceuticalsApproved
Toradol
RocheApproved
Lexapro
AbbVieApproved
Cymbalta
Jazz PharmaceuticalsApproved
Epidiolex
Jazz PharmaceuticalsApproved
Bayer Aspirin
BayerApproved
Prilosec
DDexcel Pharma Technologies Ltd.
Approved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Kenalog
BBausch Health Americas, Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Effectiveness1 trial
1 more indication
Unspecified2 trials
Injection of Dorsal Scapular n at Different Levels, Dose it Make Difference?
Completed·—·Phase 2/3·NCT04693312·60 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Depo medrol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBrii Biosciences Limited